Literature DB >> 3395370

Binding of indapamide to serum proteins and erythrocytes.

S Urien1, P Riant, A Renouard, B Coulomb, I Rocher, J P Tillement.   

Abstract

The binding of indapamide to isolated serum proteins and erythrocytes was studied in order to understand its blood distribution. In serum, indapamide was mainly bound to alpha 1-acid glycoprotein with a high affinity (K = 73.4/mM), and to albumin and lipoproteins. Indapamide was bound to erythrocytes via a saturable process with a high affinity (K = 385/mM and N = 57 microM for an hematocrit value of 0.48), and erythrocytes were the main binding component in blood (more than 80% of indapamide was associated to erythrocytes in blood). The binding to serum proteins affected indapamide distribution in blood, and alpha 1-acid glycoprotein was shown to be the more effective protein in decreasing the amount of indapamide associated to erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3395370     DOI: 10.1016/0006-2952(88)90282-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood.

Authors:  O Combes; J Barré; J C Duché; L Vernillet; Y Archimbaud; M P Marietta; J P Tillement; S Urien
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique.

Authors:  S Urien; G Bastian; C Lucas; J P Bizzari; J P Tillement
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

3.  Nicanartine improves in vitro resistance of lipoproteins to oxidation.

Authors:  E Dailly; S Urien; P Wülfroth; J P Tillement
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

4.  Binding of a new multidrug resistance modulator, S9788, to human plasma proteins and erythrocytes.

Authors:  S Urien; P Nguyen; G Bastian; C Lucas; J P Tillement
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

5.  The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.

Authors:  B Cenni; J Meyer; R Brandt; B Betschart
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

6.  Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics.

Authors:  J X Mazoit; K Samii
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

7.  Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein.

Authors:  S Urien; J Barré; C Morin; A Paccaly; G Montay; J P Tillement
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

8.  Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins.

Authors:  G Bastian; S Urien; F Brée; P Jolliet; I Rocher; O Crambes; J P Tillement
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

Review 9.  Delapril plus indapamide: a review of the combination in the treatment of hypertension.

Authors:  Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

10.  Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood.

Authors:  S Urien; F Brée; F Breillout; G Bastian; A Krikorian; J P Tillement
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.